1. Home /
    2. Altai Protocol Library /
  2. New Indication: Cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer (EMPOWER-Lung-3)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer (EMPOWER-Lung-3)

New Indication: Cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer (EMPOWER-Lung-3)
Study:
  • Double-blind, placebo-controlled, phase 3 study
  • Untreated advanced or metastatic NSCLC
  • Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154))
Efficacy:
  • mOS : 21.9 vs. 13.0 mos (HR = 0.71, p= 0.014)
  • mPFS: 8.2 vs. 5.0 mos (HR = 0.56, p < 0.001)
  • ORR: 43.3% vs. 22.7% (OR:2.68)
  • CR: 2.7% vs. 0%
Safety:
  • Any grade AEs: 95.8% vs 94.1%
  • Grade ≥3 AEs: anemia (9.9% vs. 6.5%); neutropenia (5.9% vs 5.8%)

Nat Med. 2022; 28(11): 2374–2380.

Gogishvili M et.al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

https://doi.org/10.1038/s41591-022-01977-y

Reviewed by Elvin CHALABİYEV, MD on Jan 30, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More